Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors

Journal of Cardiovascular Nursing

Volumn 23, Issue 1, 2008, Pages 20-24

  Cooper, William O ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Birth defects; Congenital abnormalities; Pregnancy

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONGENITAL MALFORMATION; EPIDEMIOLOGY; FEMALE; HUMAN; INFANT; MATERNAL AGE; MEDICAID; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; RISK FACTOR; SOCIOECONOMICS; STATISTICS; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSALITY; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MATERNAL AGE; MEDICAID; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SOCIOECONOMIC FACTORS; TENNESSEE;

EID: 37549002508     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/01.JCN.0000305052.73376.de     Document Type: Article

References (17)

1. Friedman JM. ACE inhibitors and congenital anomalies. N Engl J Med. 2006;354:2498-2500.
2. National Center for Health Statistics. National Health Care Survey. Centers for Disease Control. Available at: http://www.cdc.gov/nchs/nhcs.htm. Accessed January 17, 2005.
3. Briggs GG. Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol. 2002;45:6-21.
4. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2003;12:633-646.
5. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992;80:429-432.
6. Hu F, Morrissey P, Yao J, Xu Z. Development of AT(1) and AT(2) receptors in the ovine fetal brain. Brain Res Dev Brain Res. 2004;150:51-61.
7. Burrell JH, Hegarty BD, McMullen JR, Lumbers ER. Effects of gestation on ovine fetal and maternal angiotensin receptor subtypes in the heart and major blood vessels. Exp Physiol. 2001;86:71-82.
8. Steffensen FH, Nielsen GL, Sorensen HT, Olesen C, Olsen J. Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet. 1998;351:596.
9. Yip SK, Leung TN, Fung HY. Exposure to angiotensin-converting enzyme inhibitors during first trimester: is it safe to fetus? Acta Obstet Gynecol Scand. 1998;77:570-571.
10. Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet. 1997;350:1446-1447.
11. Chisholm CA, Chescheir NC, Kennedy M. Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure. Am J Perinatol. 1997;14:511-513.
12. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep. 1997;46:240-242.
13. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989;129:837-849.
14. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-2451.
15. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
16. Eriksson UJ, Cederberg J, Wentzel P. Congenital malformations in offspring of diabetic mothers - animal and human studies. Rev Endocr Metab Disord. 2003;4:79-93.
17. Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ. Maternal diabetes mellitus and infant malformations. Obstet Gynecol. 2002;100:925-930.